Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions

Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically significant [Grade Group (GG) ≥2] cancer, however, screening carries substantial risks, including frequent unn...

Descripción completa

Detalles Bibliográficos
Autores principales: Eyrich, Nicholas W., Morgan, Todd M., Tosoian, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Current and Future Topics on Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350244/
https://www.ncbi.nlm.nih.gov/pubmed/34430413
http://dx.doi.org/10.21037/tau-20-1151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350244/
https://www.ncbi.nlm.nih.gov/pubmed/34430413
http://dx.doi.org/10.21037/tau-20-1151

Ejemplares similares